0001104659-21-094969.txt : 20210722 0001104659-21-094969.hdr.sgml : 20210722 20210722170550 ACCESSION NUMBER: 0001104659-21-094969 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20210722 DATE AS OF CHANGE: 20210722 EFFECTIVENESS DATE: 20210722 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Akari Therapeutics Plc CENTRAL INDEX KEY: 0001541157 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 981034922 STATE OF INCORPORATION: X0 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-407386 FILM NUMBER: 211108288 BUSINESS ADDRESS: STREET 1: 24 WEST 40TH STREET STREET 2: 8TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10018 BUSINESS PHONE: (646) 350-0702 MAIL ADDRESS: STREET 1: 24 WEST 40TH STREET STREET 2: 8TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10018 FORMER COMPANY: FORMER CONFORMED NAME: Celsus Therapeutics Plc. DATE OF NAME CHANGE: 20130621 FORMER COMPANY: FORMER CONFORMED NAME: Morria Biopharmaceuticals PLC DATE OF NAME CHANGE: 20120201 D 1 primary_doc.xml X0708 D LIVE 0001541157 Akari Therapeutics Plc 75/76 WIMPOLE STREET LONDON X0 UNITED KINGDOM W1G 9RT +44 20 8004 0270 UNITED KINGDOM None Celsus Therapeutics Plc. Morria Biopharmaceuticals PLC Corporation true Clive Richardson c/o Akari Therapeutics, PLC 75/76 Wimpole Street London X0 UNITED KINGDOM W1G 9RT Executive Officer Director Peter Feldschreiber c/o Akari Therapeutics, PLC 75/76 Wimpole Street London X0 UNITED KINGDOM W1G 9RT Director Ray Prudo c/o Akari Therapeutics, PLC 75/76 Wimpole Street London X0 UNITED KINGDOM W1G 9RT Director James Hill c/o Akari Therapeutics, PLC 75/76 Wimpole Street London X0 UNITED KINGDOM W1G 9RT Director Stuart Ungar c/o Akari Therapeutics, PLC 75/76 Wimpole Street London X0 UNITED KINGDOM W1G 9RT Director David Byrne c/o Akari Therapeutics, PLC 75/76 Wimpole Street London X0 UNITED KINGDOM W1G 9RT Director Donald Williams c/o Akari Therapeutics, PLC 75/76 Wimpole Street London X0 UNITED KINGDOM W1G 9RT Director Michael Grissinger c/o Akari Therapeutics, PLC 75/76 Wimpole Street London X0 UNITED KINGDOM W1G 9RT Director Biotechnology Decline to Disclose 06b false 2021-07-07 false true true false 0 Paulson Investment Company, LLC 5670 None None 2141 W. NORTH AVE. 2ND FLOOR CHICAGO IL ILLINOIS 60647 CA CALIFORNIA CT CONNECTICUT FL FLORIDA HI HAWAII IL ILLINOIS MD MARYLAND MI MICHIGAN NV NEVADA NJ NEW JERSEY NM NEW MEXICO NY NEW YORK OH OHIO OK OKLAHOMA PA PENNSYLVANIA SC SOUTH CAROLINA TX TEXAS VA VIRGINIA WA WASHINGTON false 12318688 12318688 0 $600,000 of offering proceeds is expected to be received, and ADSs will be delivered in connection therewith, in the coming days. false 62 933000 0 Paulson Investment Company, LLC is also entitled to expense reimbursement of up to $50,000, a non-accountable expenseallowance of $10,000 and warrants to purchase an aggregate of 398,384 ADSs exercisable at $2.32 per ADS for five years. 0 Working capital purposes false Akari Therapeutics Plc /s/ Torsten Hombeck Torsten Hombeck Chief Financial Officer 2021-07-22